Recently, Paul Dryden, President of ProMedic, authored an article regarding TCI. The purpose of this special article is to explore possible regulatory paths that could lead to TCI marketing clearance or approval by the FDA, permitting clinical use of this widely available technology in the United States.

The article can be found HERE.